ACHIEVEMENT OF ARTERIAL HYPERTENSION CONTROL VIA APPLICATION OF PERINDOPRIL ARGININE AND AMLODIPINE COMBINATION

Aim. Evaluation of the opportunity to improve efficacy of arterial hypertension (AH) control using fixed combination of perindopril arginine and amlodipine.

Material and methods. Totally, 52 patients (27 men and 25 women, age 40-63 y.o.) studied, with AH 2-3 stage. All patients underwent 24-hour blood pressure monitoring (ABPM) with analysis of the data obtained: mean 24-hour pressure, velocity of morning hypertension onset for systolic BP (sBP) and diastolic BP (dBP), and variability of (Var) of PsBP (Var PsBPs, Var PsBPd). The inclusion criteria was non-sufficient control of blood pressure on the intake of voluntary combinations of ACE inhibitor and angiotensine II receptor blocker and diuretic or calcium channel blocker. For BP control, to all patients we prescribed fixed combination perindopril arginine/amlodipine with start dosage 10/5 mg (Prestance, “Les Laboratoires Servier”, France) with further possibility to increase dosage to 10 mg of perindopril arginine and amlodipine.

Results. At the background of therapy provided, 84,6% of patients reached “target” BP. Mean 24-hour sBP decreased from 139,29±1,7 to 121,17±1,26 mmHg. (р<0,05), dBP decreased from 84,49±2,06 to 73,14±1,4 (р<0,05), mean BP decreased from 102,09±1,49 to 87,96±1,12 (р<0,05). 24-hour variability of sBP significantly reduced from 15,28±0,72 to 10,21±0,42 (р<0,05), dBP from 13,46±0,72 to 10,72±0,31 (р<0,001). Parameters of morning onset (MO) after the treatment also decreased. Before treatment MO sBP was (26±4,23 mmHg/hour), with the therapy — (16,3±4,03 mmHg/hour, р<0,01); also, MO dBP decreased from 24,7±2,35 mmHg/hour to 12±1,61 mmHg hour, р<0,01).

Conclusion. Replacement of therapy for non-controlled AH with voluntary combinations of antihypertensive medications by fixed combination of perindopril arginine/amlodipine (Prestance) facilitated the effectiveness of AH control. Usage of the fixed combination of perindopril arginine/amlodipine in 84,6% helped to reach target values of BP. The effectiveness of BP control achieved, followed with ABPM data of 24-hour BP values decrease during the day and night, variability and velocity of morning BP onset. Usage of the drug studied showed good tolerability and high adherence of patients to treatment.

1. Diagnostics and treatment of arterial hypertension. Clinical practice guidelines. The Ministry of Health of the Russian Federation. Moscow, 2013. http://www.gipertonik.ru/files/recommendation/Recommendations_hypertension.docx. (Диагностика и лечение артериальной гипертонии. Клинические рекомендации. Министерство здравоохранения РФ. Москва, 2013. http://www.gipertonik.ru/files/recommendation/Recommendations_hypertension.docx.)

2. Sirenko Yu. Dihydropyridine calcium antagonists — a new reserve to reduce the risk of complications in arterial hypertension. Arterial hypertension 2010; 1(9): 47-52. Russian (Сиренко Ю.Н. Дигидропиридиновые антагонисты кальция — новый резерв снижения риска осложнений при артериальной гипертензии. Артериальная гипертензия 2010; 1(9): 47-52).

3. Palatini P. Role of elevated heart rate in the development of cardiovascular disease in hypertension. Hypertension 2011; 58: 745-50.

4. Lewington S, Clarke R, Qizilbash N, et al. Age specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903.

5. Meurin P. The ASCOT trial: clarifying the role of ACE inhibition in the reduction of cardiovascular events in patients with hypertension. American Journal of Cardiovascular Drugs 2006; 6: 327-34.

6. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003; 21: 707-16.

7. Brown DW, Giles WH, Greenlund KJ. Blood pressure parameters and risk of total stroke, NHANES II mortality study. Am J Hypertens 2007; 20: 338-41.

8. Karpov YA, Deev AD, et al. Uncontrolled arterial hypertension — new possibilities in solving the problems of increasing the effectiveness of treatment. Cardiology 2012; 2: 29-35. Russian (Карпов Ю.А., Деев А.Д. и др. Неконтролируемая артериальная гипертония — новые возможности в решении проблемы повышения эффективности лечения. Кардиология 2012; 2: 29-35.

9. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 31: 1281-357.

10. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ЕОГ/EОК guidelines for the management of arterial hypertension. Eur. Heart J 2013; 34 (28): 2159-219.

11. Gradman A, Basile J, Carter B, et al. Combination therapy in hypertension. Journal of the American Society of Hypertension 2010; 4: 42-50.

12. Bahl VK, et al. Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice. Results from theSTRONG prospective, Observational, Multicenter Study. Cardiovasc Drug 2009; 9: 136-42.

13. Girish MP, Bahl V, Jadhav U, et al. Blood pressure control of fixed dose, perindopril/amlodipine combination treatment in hypertensive patients uncontrolled on monotherapy or on two drug combination therapy. J Hypertens 2010; 28 (E-suppl. A): e98 [Abstract].

14. Kjeldsen S, Jamerson K, Bakris G, et al. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Pressure 2008; 17: 7-17.